Cite
Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial.
MLA
Xu, Rui-Hua, et al. “Modified XELIRI (Capecitabine plus Irinotecan) versus FOLFIRI (Leucovorin, Fluorouracil, and Irinotecan), Both Either with or without Bevacizumab, as Second-Line Therapy for Metastatic Colorectal Cancer (AXEPT): A Multicentre, Open-Label, Randomised, Non-Inferiority, Phase 3 Trial.” Lancet Oncology, vol. 19, no. 5, May 2018, pp. 660–71. EBSCOhost, https://doi.org/10.1016/S1470-2045(18)30140-2.
APA
Xu, R.-H., Muro, K., Morita, S., Iwasa, S., Han, S. W., Wang, W., Kotaka, M., Nakamura, M., Ahn, J. B., Deng, Y.-H., Kato, T., Cho, S.-H., Ba, Y., Matsuoka, H., Lee, K.-W., Zhang, T., Yamada, Y., Sakamoto, J., Park, Y. S., & Kim, T. W. (2018). Modified XELIRI (capecitabine plus irinotecan) versus FOLFIRI (leucovorin, fluorouracil, and irinotecan), both either with or without bevacizumab, as second-line therapy for metastatic colorectal cancer (AXEPT): a multicentre, open-label, randomised, non-inferiority, phase 3 trial. Lancet Oncology, 19(5), 660–671. https://doi.org/10.1016/S1470-2045(18)30140-2
Chicago
Xu, Rui-Hua, Kei Muro, Satoshi Morita, Satoru Iwasa, Sae Won Han, Wei Wang, Masahito Kotaka, et al. 2018. “Modified XELIRI (Capecitabine plus Irinotecan) versus FOLFIRI (Leucovorin, Fluorouracil, and Irinotecan), Both Either with or without Bevacizumab, as Second-Line Therapy for Metastatic Colorectal Cancer (AXEPT): A Multicentre, Open-Label, Randomised, Non-Inferiority, Phase 3 Trial.” Lancet Oncology 19 (5): 660–71. doi:10.1016/S1470-2045(18)30140-2.